2026-04-13T00:56:08Zhttps://recercat.cat/oai/request

oai:recercat.cat:2445/1809672025-12-05T11:54:54Zcom_2072_1057col_2072_478916col_2072_478917col_2072_478927

00925njm 22002777a 4500 dc Velasco Ortega, Eugenio author Sierra Baztan, Angela author Jiménez Guerra, Alvaro author España López, Antonio author Ortiz García, Ivan author Núñez Márquez, Enrique author Moreno Muñoz, Jesús author Rondón Romero, José Luis author López López, José, 1958- author Monsalve Guil, Loreto author 2021-11-02T14:35:30Z 2021-11-02T14:35:30Z 2021-09-22 2021-10-28T09:56:32Z Introduction: The aim of this study was to show the long-term clinical outcomes of implants placed in maxillary sinus floor augmentation (MFSA) using beta-tricalcium phosphate (β-TCP). Patients and methods: Maxillary patients were diagnosed for MFSA and used beta- β-TCP. After the lateral sinus surgery, implants were loaded at 6 months with restorations. The clinical follow-up was at 10 years. Results: One hundred and one patients (58 females and 43 males) were treated with MFSA. Twenty-nine patients (28.7%) had a history of periodontitis. Thirty-three patients (32.7%) were smokers. One hundred and twenty-one MFSA, 81 unilateral and 20 bilateral sites, with 234 implants were performed. The average vertical bone height available was 4.92 ± 1.83 mm. The average vertical bone gain obtained was 6.95 ± 2.19 mm following MFSA. The implant cumulative survival rate was 97.2%. Three implants (1.3%) were lost during the healing period. Six implants (2.6%) were lost by peri-implantitis. One hundred and fifteen restorations were placed in the patients. Mean marginal bone loss was 1.93 mm ± 1.03 mm. Six patients (27.3%) showed technical complications. Thirty-six implants (15.3%) in 14 patients (13.9%) were associated with peri-implantitis. Conclusions: This study indicates that treatment with implant-supported restoration by MFSA using β-TCP constitutes a successful implant approach. Periodontitis Pròtesis internes Periodontitis Stents (Surgery) Long-Term Clinical Study of Implants Placed in Maxillary Sinus Floor Augmentation Using Beta-Tricalcium Phosphate